Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLoans and Notes ReceivablesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Gyre Therapeutics (GYRE) Leases (2019 - 2025)

Gyre Therapeutics has reported Leases over the past 7 years, most recently at $1.1 million for Q4 2025.

  • Quarterly Leases fell 37.79% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, down 37.79% year-over-year, with the annual reading at $1.1 million for FY2025, 37.79% down from the prior year.
  • Leases was $1.1 million for Q4 2025 at Gyre Therapeutics, down from $1.8 million in the prior quarter.
  • Over five years, Leases peaked at $3.1 million in Q2 2021 and troughed at $17000.0 in Q1 2023.
  • The 5-year median for Leases is $1.7 million (2022), against an average of $1.5 million.
  • Year-over-year, Leases tumbled 99.24% in 2023 and then surged 2252.94% in 2024.
  • A 5-year view of Leases shows it stood at $2.7 million in 2021, then plummeted by 75.73% to $666000.0 in 2022, then fell by 26.58% to $489000.0 in 2023, then skyrocketed by 271.78% to $1.8 million in 2024, then plummeted by 37.79% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Leases are $1.1 million (Q4 2025), $1.8 million (Q4 2024), and $2.0 million (Q3 2024).